Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Synthelis Raises EUR 610,000

Published: Wednesday, January 22, 2014
Last Updated: Tuesday, January 21, 2014
Bookmark and Share
This initial funding enables the commercial roll-out of Synthelis’ membrane protein production using acellular technology.

Synthelis has announced that it has secured initial backing of EUR 610,000 from a group of French investors comprising Rhone-Alpes Creation, Alpes Developpement Durable Investissement (A2D-Invest), Sud Rhone-Alpes Capital, Viaduc and the Savoy and Grenoble Business Angels networks.

The aim of this initial round of funding is to speed up the development of toll manufacturing services for membrane proteins for use by R&D departments in the pharmaceutical and biotechnology industries. The funding also gives the company scope to consolidate and expand its functional and structural characterization services.

“This investment is an important step for Synthelis, allowing us to strengthen our team of scientists and invest in essential new equipment to optimize production and enhance our services,” explains Bruno Tillier, CEO of Synthelis. “Synthelis can now accelerate its commercial development, both in France and internationally.”

Founded in 2011 by Bruno Tillier to build on Professor Jean-Luc Lenormand's work at the TIMC-TheREx laboratory, part of the Universite Joseph Fourier in Grenoble, France, Synthelis develops and leverages an innovative patented technology for the acellular production of membrane proteins in the presence of liposomes.

The technology preserves the structure and the natural properties of these molecules, along with their ‘transportability’. This removes a major technological stumbling block in bio-production: previously, faithful reproductions of natural membrane proteins were difficult to manufacture in sufficient quantities.

Membrane proteins account for 60 per cent of current therapeutic targets. These membrane proteins (so called because they are embedded in the membrane which separates the cell's internal and external environments) play a role in ensuring that the cell - and therefore the organism as a whole - functions properly. Membrane protein abnormalities are also implicated in many diseases such as cancers, neuro-degenerative diseases and metabolic, genetic, immune and inflammatory disorders. In 2012, the market in which Synthelis currently operates - R&D services for the pharmaceutical industry - was valued at EUR 20 billion, with an annual growth rate of 13 per cent (source: Equity Research).

“We are pleased to be contributing to the development plans of what is a very promising young company. This is a classic case of a start-up founded on a technology coming out of a university laboratory needing financial support to make its mark as a leader in its field. The role of regional funds such as Rhone Alpes Creation and the Business Angels is to help innovative businesses like Synthelis,” adds Gwenael Hamon, senior business manager at Rhone Alpes Creation.

In two years, Synthelis has produced over 50 membrane proteins as part of more than 20 projects undertaken in conjunction with internationally-renowned pharmaceutical organizations. The success rate for protein expression across all the work undertaken by Synthelis to date is in excess of 90 per cent.

Once the initial commercial objectives have been achieved, new investment is planned in order to industrialize Synthelis’ acellular procedure and consolidate its leading position in this market. The funding will open up the market for contract manufacturing services, complementing and ensuring continuity with the existing contract research offering.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
The Genetic Roots of Adolescent Scoliosis
Scientists at the RIKEN Center for Integrative Medical Sciences in collaboration with Keio University in Japan have discovered a gene that is linked to susceptibility of Scoliosis.
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
Understanding the Molecular Origin of Epigenetic Markers
Researchers at IRB Barcelona discover the molecular mechanism that determines how epigenetic markers influence gene expression.
HIV Susceptibility Linked to Little-Understood Immune Cell Class
High levels of diversity among immune cells called natural killer cells may strongly predispose people to infection by HIV, and may be driven by prior viral exposures, according to a new study.
Diagnostic Test Developed for Enterovirus D68
researchers at Washington University School of Medicine in St. Louis have developed a diagnostic test to quickly detect enterovirus D68 (EV-D68), a respiratory virus that caused unusually severe illness in children last year.
How a Kernel Got Naked and Corn Became King
Ten thousand years ago, a golden grain got naked, brought people together and grew to become one of the top agricultural commodities on the planet.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
New Material Opens Possibilities for Super-Long-Acting Pills
A pH-responsive polymer gel could create swallow able devices, including capsules for ultra-long drug delivery.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!